Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction
https://doi.org/10.14341/2072-0351-5811
Abstract
Aim.
Evaluation of the dynamics of the markers of insulin resistance in patients with myocardial infarction with ST-segment elevation with andwithout type 2 diabetes mellitus in the acute and early recovery period of the disease.
Materials and methods.
The study included 95 patients with myocardial infarction and 60 patients with myocardial infarction and type 2 diabetes.The control group consisted of 30 persons. We all studied at 1 st and 12 th day of myocardial infarction was determined by the content of free fattyacids, glucose, C-peptide, insulin in serum and plasminogen activator inhibitor in blood plasma. In addition, the 12 th day was determined postprandialglycemic, insulin and C-peptide 2h after a standard carbohydrate breakfast.
Results.
It is established that during myocardial infarction accompanied by the development of insulin resistance, characterized by postprandialglycemia and insulinemia, as well as the presence of elevated levels of free fatty acids, plasminogen activator inhibitor.
Conclusion.
The definition of metabolic markers of insulin resistance may be of great predictive capacity for assessing the risk of both acute coronaryevents and select tactics to further treatment
Evaluation of the dynamics of the markers of insulin resistance in patients with myocardial infarction with ST-segment elevation with andwithout type 2 diabetes mellitus in the acute and early recovery period of the disease.
Materials and methods.
The study included 95 patients with myocardial infarction and 60 patients with myocardial infarction and type 2 diabetes.The control group consisted of 30 persons. We all studied at 1 st and 12 th day of myocardial infarction was determined by the content of free fattyacids, glucose, C-peptide, insulin in serum and plasminogen activator inhibitor in blood plasma. In addition, the 12 th day was determined postprandialglycemic, insulin and C-peptide 2h after a standard carbohydrate breakfast.
Results.
It is established that during myocardial infarction accompanied by the development of insulin resistance, characterized by postprandialglycemia and insulinemia, as well as the presence of elevated levels of free fatty acids, plasminogen activator inhibitor.
Conclusion.
The definition of metabolic markers of insulin resistance may be of great predictive capacity for assessing the risk of both acute coronaryevents and select tactics to further treatment
About the Authors
Olga Viktorovna Gruzdeva
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo
Olga Leonidovna Barbarash
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo; Kemerovskaya State Medical Academy, Kemerovo
Olga Evgen'evna Akbasheva
Siberian State Medical University, Tomsk
Tatiana Sergeevna Fedorova
Siberian State Medical University, Tomsk
Elena Ivanovna Palicheva
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo; Kemerovskaya State Medical Academy, Kemerovo
Vasiliy Vasil'evich Kashtalap
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo
Yulia Alexandrovna Dyleva
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo
Anna Alexandrovna Silonova
Kemerovskaya State Medical Academy, Kemerovo
Ekaterina Vladimirovna Sionina
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo
Evgenia Gennad'evna Uchasova
Research Institute of complex problems of cardiovascular disease RAMS, Kemerovo
References
1. Collet J.P., Montalescot G., Vicaut E. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality // Circulation. - 2003. - Vol. 108. - P. 391-394.
2. Ishihara M., Kojima S., Sakamoto T. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era // J. Am. Heart. - 2005. - Vol. 150. - P. 814-820.
3. Alessi M., Juhan-Vague I. PAI-1 and the Metabolic Syndrome // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2006. - Vol. 26. - P. 2200-2207.
4. Lopez-Alemany R., Redondo J. M., Nagamine Y., Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with avb3 integrin for vitronectin binding // J. Eur. Biochem. - 2003. - Vol. 270. - P. 814-821.
5. Campbell I.W. The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus // Brit. J. of Diabetes & Vasc. Dis. - 2006. - Vol. 6. - P. 207-215.
6. Cefalu W.T. Insulin resistance: cellular and clinical concepts // Exp. Biol. Med. - 2001. - Vol. 226. - P. 13-26.
7. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies // B.M.J. - 2006. - Vol. 332. - P. 73-78.
8. Leclercq I.A., Da Silva Morais A., Schroyen B., Van Hul N., Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences // J. Hepatol. - 2007. - Vol. 47. - № 1. - P. 142-156.
9. Lopaschuk G.D., Ussher J.R., Folmes C.D.L., Jaswal J.S., Stanley W.C. Myocardial Fatty Acid Metabolism in Health and Disease // Physiol. Rev. - 2010. - Vol. 90. - P. 207-258.
10. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., Quon M.L. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans // J. Clin. Endocrinol. Metab. - 2000. - Vol. 85. - P. 2402-2410.
11. Juhan-Vague I., Morange P.E., Frere C., Aillaud M.F., Alessi M.C., Hawe E., Boquist S., Tornvall P., Yudkin J.S., Tremoli L., Margaglione M., Di Minno G., Hamsten A., Humphries S.E. The Plasminogen Activator Inhibitor-1 -675 4G/5G genotype influences the risk of Myocardial Infarction associated with elevated plasma proinsulin/insulin levels in men from Europe // J. Thromb. Haemost. - 2003. - Vol. 1. - P. 2322-2329.
12. Liang X., Kanjanabuch T., Mao S.L., Hao Chuan-Ming, Tang Yi-Wei, Declerck P.J., Hasty A.H., Wasserman D.H., Fogo A.B., Ma Li-Jun Plasminogen activator inhibitor-1 modulates adipocyte differentiation // J. Physiol. Endocrinol. Metab. - 2006. - Vol. 290. - P. 10-113.
Review
For citations:
Gruzdeva O.V., Barbarash O.L., Akbasheva O.E., Fedorova T.S., Palicheva E.I., Kashtalap V., Dyleva Yu.A., Silonova A.A., Sionina E.V., Uchasova E.G. Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction. Diabetes mellitus. 2011;14(4):18-23. (In Russ.) https://doi.org/10.14341/2072-0351-5811
Views:
819
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
